| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
QuidelOrtho Corporation$18.23
0 (0%)
Market Cap
808.75 M
EPS
-17.82
P/E Ratio
-
Value Trade
24.76 M
SEC Financials
Q1 2026Dilution Risk
50%Revenue
619.80 M
R&D Expenses
44.90 M
Operating CF
-33.00 M
Total Assets
5.63 B
Total Liabilities
3.78 B
Equity
1.85 B
D/E Ratio
12,345
4.13 %
Week
-2.47 %
1 Month
-49.32 %
3 Month
-47.12 %
6 Month
-90.2 %
5 Year
131.41 %
All Time
Cash Data
Cash Position
140.40 M
Monthly Burn
11.00 M
Runway
10.6 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
361.24 K
52 Week Range
9.92 - 35.58
% held by Insiders
1.18 %
% held by Institutions
127.56 %
Enterprise Value
3.54 B
Total Shares
68.06 M
Short %
17.08 %
Float Shares
67.45 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QDEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QDEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QDELQuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation announced the approval of an Inducement Grant of 356,555 restricted stock units (RSUs) to Micah Young, the new Chief Financial Officer. This grant, approved by the Compensation Committee, is part of the 2026 Inducement Plan and aims to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on Mr. Young's continued employment.
Read more →QDELQuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young succeeds Joseph M. Busky, who will assist in the transition. Young has extensive experience in medical technology finance and aims to enhance profitability and shareholder value at QuidelOrtho.
Read more →QDELQuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians...
QuidelOrtho and the Allo Hope Foundation have announced a collaboration to enhance prenatal care for women facing maternal red blood cell alloimmunization. This partnership aims to provide education, early testing, and improved connections between healthcare providers and patients. The initiative seeks to address gaps in care, particularly for underserved populations, and will produce educational materials for families and lab technicians.
Read more →QDELWhen Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho Corporation has released a podcast episode discussing hemolytic disease of the fetus and newborn (HDFN), emphasizing the impact of maternal alloimmunization. The episode highlights the importance of awareness, timely diagnostics, and coordinated care to improve outcomes. Despite advancements, significant gaps in understanding and care persist, affecting patient management.
Read more →QDELQuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
QuidelOrtho Corporation announced its participation in two upcoming investor conferences in June 2026. The management team will present at the William Blair 46th Annual Growth Stock Conference and engage in a fireside chat at the Jefferies Global Healthcare Conference. Interested parties can access the events via the company's Investor Relations page.
Read more →QDEL▼ -6%on this news
QuidelOrtho Reports First Quarter 2026 Financial Results
QuidelOrtho Corporation reported its first-quarter financial results for 2026, highlighting a weaker respiratory season and disruptions in key markets. Despite these challenges, the company remains optimistic about its growth prospects, particularly following its acquisition of LEX Diagnostics and the launch of new products. The company has updated its financial guidance for the year, factoring in current market dynamics.
Read more →QDEL▼ -6.1%on this newsshared move
QuidelOrtho Reports First Quarter 2026 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced...
QuidelOrtho Corporation reported its first quarter 2026 financial results, revealing a total revenue of $620 million, a decline from the previous year. The company experienced a significant drop in Point of Care revenue, attributed to a weaker respiratory season and disruptions in China. Despite these challenges, QuidelOrtho completed the acquisition of LEX Diagnostics, which is expected to bolster its growth in molecular diagnostics. The company has updated its full-year financial guidance, reflecting current market dynamics.
Read more →QDEL▼ -5.5%on this news
Understanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Corporation's latest podcast episode discusses the concerning rise in congenital syphilis cases in the U.S., despite a decline in early-stage infections. Hosted by Josh Casey, the episode features insights from Andrea Ott-Vasconi on CDC data and emphasizes the need for improved diagnostic strategies and healthcare workflows. The discussion highlights missed screening opportunities and actionable steps to enhance prenatal care.
Read more →QDELQuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation has successfully acquired LEX Diagnostics for approximately $100 million, enhancing its molecular diagnostics capabilities. The LEX VELO System, which has received FDA clearance, offers rapid RT-PCR testing for Influenza A, Influenza B, and COVID-19. The company plans to launch this system commercially in the U.S. later this year, aiming to improve patient outcomes through faster diagnostics.
Read more →QDELTTP Group Announces the Sale of LEX Diagnostics
TTP Group has announced the sale of LEX Diagnostics. Details regarding the transaction and its implications for TTP Group and LEX Diagnostics are not provided in the article. The announcement suggests a strategic move by TTP Group, although specifics are lacking.
Read more →QDEL▼ -27.5%on this newsshared move
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
QuidelOrtho Corporation announced preliminary unaudited revenue of $615-$620 million for Q1 2026, driven by a weaker respiratory season and slower sales in China. The company remains optimistic about its core business, which constitutes over 70% of total revenue. However, it faces challenges from external factors, including geopolitical issues and reimbursement rate changes. A detailed financial report is expected on May 5, 2026.
Read more →QDELNathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky, who has over 25 years of experience in legal and governance roles, succeeds Michelle Hodges, who is retiring. He aims to support the company's mission of advancing diagnostics and improving patient care.
Read more →QDELFaster Cardiac Answers with High‑Sensitivity Troponin QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr....
QuidelOrtho Corporation has launched episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom. The episode discusses the impact of high-sensitivity troponin on early cardiac diagnosis and its role in enhancing emergency department efficiency. This advancement is expected to significantly improve patient care in acute settings.
Read more →QDELQuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that...
QuidelOrtho Corporation announced that its management team will present at the 47th Annual Raymond James Institutional Investor Conference on March 3, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations page. QuidelOrtho continues to focus on advancing in vitro diagnostics to improve patient care.
Read more →QDEL퀴델오쏘, 글로벌 면역분석 포트폴리오 확대 위한 전략적 공급 계약 체결 퀴델오쏘(QuidelOrtho)가 글로벌 면역분석 포트폴리오 확대 및 미국 외 선별 시장에서 확장 가능한 고품질의 비용 효율적인 솔루션에 대한 고객 접근성을 가속하기 위해 리포트로닉 테크놀로지(Lifotronic Technology Co., Ltd., 리포트로닉...
QuidelOrtho has announced a partnership with Lifotronic Technology Co., Ltd. to enhance diagnostic capabilities in the medical field. This collaboration focuses on improving the efficiency of diagnostic tests and aims to provide better healthcare solutions. The partnership is expected to leverage Lifotronic's technology to advance QuidelOrtho's product offerings.
Read more →QDELQuidelOrtho firma un acuerdo de suministro estratégico para ampliar su cartera global de inmunoensayos QuidelOrtho ha firmado un acuerdo de suministro estratégico a largo plazo con Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd.,...
QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to enhance QuidelOrtho's global immunoassay portfolio and improve customer access to scalable, high-quality, and cost-effective solutions in key international markets outside the United States.
Read more →QDELQuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code:...
QuidelOrtho has signed a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to expand QuidelOrtho's global immunoassay portfolio and enhance customer access to high-quality, cost-effective solutions in select international markets. The agreement is expected to accelerate the company's growth outside the United States.
Read more →QDELQuidelOrtho geht strategische Liefervereinbarung zur Erweiterung des globalen Immunoassay-Portfolios ein QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co., Ltd.,...
QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to expand QuidelOrtho's global immunoassay portfolio and enhance customer access to scalable, high-quality, and cost-effective solutions in selected international markets outside the United States.
Read more →QDELQuidelOrtho、グローバルなイムノアッセイ・ポートフォリオを拡大する戦略的供給契約を締結 QuidelOrthoはLifotronic Technology Co, Ltd. (Lifotronic Technology Co., Ltd.,...
QuidelOrtho has entered into a long-term supply agreement with Lifotronic Technology Co., Ltd. This partnership will enhance QuidelOrtho's global market presence and improve the quality and efficiency of its diagnostic products. The new product is designed to meet specific testing criteria and is expected to facilitate better access to diagnostics.
Read more →QDELQuidelOrtho conclut un accord d'approvisionnement stratégique pour élargir son portefeuille mondial d'immunoessais QuidelOrtho a conclu un accord d'approvisionnement stratégique à long terme avec Lifotronic Technology Co, Ltd. (Lifotronic Technology Co., Ltd.,...
QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to expand QuidelOrtho's global immunoassay portfolio and enhance customer access to scalable, high-quality, and cost-effective solutions in international markets outside the United States.
Read more →QDEL▼ -17.6%on this newsshared move
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
QuidelOrtho Corporation reported strong financial results for Q4 and FY25, highlighting a transition to a more stable diagnostics business. The company achieved notable growth in Labs and TRIAGE™ segments, along with significant margin expansion. Looking ahead, QuidelOrtho anticipates improved free cash flow in FY26, although the retirement of CFO Joseph M. Busky raises some concerns about future financial management.
Read more →QDELQuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced...
QuidelOrtho Corporation reported its fourth quarter and full-year 2025 financial results, showing a total revenue of $2.73 billion. The company experienced growth in its Labs and TRIAGE™ segments, alongside a significant improvement in adjusted EBITDA margin. However, the overall financial performance was impacted by a substantial net loss attributed to a goodwill impairment charge. Looking ahead, QuidelOrtho anticipates improved free cash flow and continued growth in FY26.
Read more →QDELQuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA,...
QuidelOrtho Corporation has been awarded the Excellence Services Label for its Customer and Technical Services in EMEA, becoming the first medical device company to achieve this recognition. Additionally, the company received a Gold Stevie Award for Customer Service Success and a Bronze Stevie Award for AI & Tech Focused Digital Transformation Team of the Year. These accolades reflect QuidelOrtho's dedication to delivering high-quality customer experiences and innovation in service.
Read more →QDELStrengthening the blood supply: Awareness, challenges and donor impact QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring...
QuidelOrtho Corporation has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens discussing the challenges facing today's blood supply. The episode highlights the impact of emergencies on blood demand, the need for targeted donor recruitment, and the role of automation in enhancing safety. Mullens emphasizes the importance of year-round donations to ensure patient care and safety.
Read more →QDEL▼ -10.1%on this newsshared move
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
QuidelOrtho Corporation will announce its financial results for Q4 and the full year 2025 on February 11, 2026. Following this release, a conference call will be held to discuss the results. Interested parties can access the call via the company's website or by phone. A replay will be available afterward.
Read more →QDEL▼ -10.1%on this newsshared move
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report ...
QuidelOrtho Corporation will announce its financial results for the fourth quarter and full year 2025 on February 11, 2026. Following the announcement, a conference call will be held to discuss the results. Interested parties can access the call via the company's website or by phone. A replay will be available post-event.
Read more →QDELInnovating Diagnostics and What's Next QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring...
QuidelOrtho Corporation has released Episode 54 of its Science Bytes podcast, featuring insights from Dr. Jonathan Siegrist on innovative diagnostic solutions. The episode discusses advancements such as faster cardiac care, non-invasive gastrointestinal health tests, and the integration of AI in diagnostics. These innovations aim to enhance patient outcomes and streamline clinical workflows.
Read more →QDEL▲ +9.2%on this news
QuidelOrtho To Participate In Upcoming Investor Conferences QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team...
QuidelOrtho Corporation announced its participation in two upcoming investor conferences, the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025, and the Citi Global Healthcare Conference on December 3, 2025. Management will engage in fireside chats at both events, highlighting the company's commitment to investor relations and diagnostics advancement. Interested parties can access the live webcasts through the company's Investor Relations page.
Read more →QDELThe Power of Prevention: Detecting Diabetes Before It Strikes QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian ...
QuidelOrtho Corporation has released Episode 53 of its Science Bytes podcast, featuring Dr. Qian Ding discussing the importance of early diabetes detection. The episode highlights how proactive testing can shift care from reactive to preventive, utilizing modern laboratory platforms and biomarkers. Key insights include the economic benefits of early intervention and the importance of equitable testing strategies.
Read more →QDELQuidelOrtho Reports Third Quarter 2025 Financial Results Total revenue of $700 million excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum Successful
QuidelOrtho Corporation reported its third quarter 2025 financial results, with total revenues of $700 million, representing a 4% decrease from the previous year. The decline was primarily attributed to lower COVID-19 and Donor Screening revenues. Despite this, the company announced a successful debt refinancing which enhances financial flexibility and reported a rise in adjusted EBITDA margin to 25%. Adjusted diluted earnings per share were $0.80 for this quarter, slightly down from $0.85 in the prior year.
Read more →QDELQuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro...
QuidelOrtho Corporation has received FDA 510(k) clearance for its VITROS hs Troponin I Assay, which enables high-sensitivity measurement of cardiac troponin I in human plasma. This assay aims to assist in diagnosing myocardial infarction, thereby improving patient care in emergency settings. The rollout for U.S. laboratories is set to begin later this year.
Read more →QDELInformatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring...
QuidelOrtho Corporation has released Episode 52 of its Science Bytes podcast, featuring George Wierschem discussing the transformative role of informatics in clinical decision-making. The episode highlights how informatics improves laboratory operations by connecting instruments and data systems, enhancing efficiency, data integrity, and patient care. Key insights include the importance of automation, security, and accountability in laboratory settings.
Read more →QDELQuidelOrtho to Report Third Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report ...
QuidelOrtho Corporation will report its financial results for Q3 2025 on November 5, 2025, after market close. A conference call to discuss these results is scheduled for the same day at 2:00 p.m. PT. Interested parties can access the call via the company's website or by phone.
Read more →QDELQuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025 QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine...
QuidelOrtho Corporation will showcase its advancements in transfusion medicine at the AABB 2025 Annual Meeting. The company highlights the FDA-approved MTS DAT Card and its ORTHO VISION Platform, which enhances testing efficiency. Educational sessions and product demonstrations will focus on improving laboratory performance and patient outcomes.
Read more →QDELThrough Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released the latest episode of its Science Bytes podcast,...
QuidelOrtho Corporation has released a new episode of its Science Bytes podcast featuring Dr. Terry O'Neil. In this episode, Dr. O'Neil discusses the challenges of diagnosing respiratory illnesses due to overlapping symptoms. He emphasizes the importance of rapid testing for guiding treatment and protecting community health.
Read more →QDELQuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of...
QuidelOrtho Corporation has launched the QUICKVUE Influenza + SARS Test, enhancing its QUICKVUE portfolio. This rapid immunoassay allows for simultaneous detection of influenza A, influenza B, and SARS-CoV-2 from a single sample, providing results in as little as 10 minutes. The test is aimed at improving diagnosis in professional healthcare settings, facilitating timely treatment decisions.
Read more →QDELQuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed...
QuidelOrtho Corporation will participate in the Baird 2025 Global Healthcare Conference on September 10, 2025. The management team will host a fireside chat at 3:10 p.m. ET. Interested parties can access the live webcast through the company's Investor Relations page. QuidelOrtho continues to lead in innovative in vitro diagnostic technologies.
Read more →QDELScience Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro...
QuidelOrtho Corporation is addressing public health concerns as schools reopen and respiratory virus season approaches. The company is sharing insights from Dr. Jonathan Temte, a respected expert in family medicine and community health. This initiative aims to inform and protect students and communities during this critical time.
Read more →QDELQuidelOrtho Completes Debt Refinancing QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed...
QuidelOrtho Corporation has completed a series of transactions to refinance its debt structure, which includes a $1.15 billion Term Loan A and a $1.45 billion Term Loan B. This refinancing aims to extend debt maturities and reduce amortization payments, thereby enhancing the company's financial flexibility and supporting future growth. CFO Joseph Busky emphasized the priority of reducing total debt and improving cash flow.
Read more →QDELQuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive...
QuidelOrtho Corporation has appointed Erich Wolff as Executive Vice President of Strategy & Corporate Development. Wolff, with extensive experience in healthcare and diagnostics, will lead the company's strategic initiatives and business development efforts. His previous roles include significant positions at Partners Group, BD, and Medtronic, where he drove transformational growth strategies.
Read more →QDEL▲ +7.5%on this news
QuidelOrtho Launches Certified Analyzer Program QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic...
QuidelOrtho Corporation has introduced a Certified Analyzer Program aimed at enhancing access to high-quality diagnostic testing in underserved U.S. communities. This initiative is specifically designed for small hospitals and clinics, providing certified VITROS™ analyzers that ensure reliable results at a reduced cost. The program is expected to significantly benefit rural healthcare facilities.
Read more →QDELQuidelOrtho Reports Second Quarter 2025 Financial Results ― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million...
QuidelOrtho Corporation reported its financial results for the second quarter of 2025, showing total revenue of $614 million, a decrease from $637 million in the previous year. Despite a decline in respiratory revenue driven by lower COVID-19 sales, the company achieved a 4% growth in labs revenue and improved its adjusted EBITDA margin. The company reiterated its full-year financial guidance amidst ongoing operational challenges.
Read more →QDELQuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory...
QuidelOrtho has been awarded three accolades at the 2025 IMV ServiceTrak Awards, recognizing their excellence in customer satisfaction and service performance. The company achieved top rankings in several categories, including overall system performance and training. Their commitment to customer-focused solutions has led to a significant improvement in their Net Promoter Score, indicating enhanced customer loyalty.
Read more →QDELUrgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between...
The latest episode of QuidelOrtho Science Bytes discusses the urgent need for early drug detection in emergency care to combat rising overdose deaths. Featuring insights from Vonda McAllister, the episode highlights the challenges posed by potent synthetic drugs and the limitations of current treatments like Narcan. It emphasizes the importance of rapid diagnostic testing and continuous monitoring in improving patient outcomes.
Read more →QDELQuidelOrtho to Report Second Quarter 2025 Financial Results QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed...
QuidelOrtho Corporation will report its second quarter 2025 financial results on August 5, 2025. The report will be followed by a conference call at 2:00 p.m. PT to discuss the results. Interested parties can access the call via the company's website or by phone. A replay will be available post-event.
Read more →QDELReal Labs, Actual Decisions With Actionable Six Sigma Metrics How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) ...
QuidelOrtho Corporation will present a session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, focusing on how Six Sigma insights can enhance laboratory performance. The session will feature a panel of experts discussing the application of QuidelOrtho's Six Sigma tools and real lab data to drive quality outcomes. This initiative reflects QuidelOrtho's dedication to improving diagnostic processes.
Read more →QDELQUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA) QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and...
QuidelOrtho Corporation and BÜHLMANN Laboratories AG have launched two new assays, the fCAL turbo and fPELA turbo, on QuidelOrtho's VITROS Systems. These assays are designed to improve the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency. The fCAL turbo assay helps differentiate IBD from irritable bowel syndrome, while the fPELA turbo assay assesses pancreatic function.
Read more →QDELQuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed...
QuidelOrtho Corporation has appointed Devon Burek as Senior Vice President of Global Quality and Sergio Gadaleta as Senior Vice President of Clinical and Regulatory Affairs. These appointments aim to enhance operational excellence and product quality while supporting the company's global growth strategy. The new executives are expected to drive innovation in regulatory affairs.
Read more →QDELQuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed...
QuidelOrtho Corporation announced a strategic shift in its molecular diagnostics approach, intending to acquire LEX Diagnostics upon FDA clearance. The acquisition, valued at approximately $100 million, aims to enhance QuidelOrtho's offerings in point-of-care testing. Additionally, the company will discontinue the development of its Savanna platform, citing a focus on more promising opportunities.
Read more →QDEL▼ -5%on this news
QuidelOrtho Announces Appointment of Two Independent Directors to its Board Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to
QuidelOrtho Corporation announced the appointment of John R. Chiminski and R. Scott Huennekens as independent directors to its board, effective December 6, 2024. This decision is aimed at strengthening the board's leadership and operational expertise, with both appointees bringing extensive experience in the healthcare sector. CEO Brian J. Blaser expressed optimism that their involvement will help execute the company's transformational strategy and improve financial results. The appointments stem from a thorough search process conducted by the Nominating and Corporate Governance Committee.
Read more →QDELQuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
QuidelOrtho Corporation has announced the pricing of a secondary offering of 8,260,183 shares of its common stock by Carlyle Partners VI Cayman Holdings, L.P. The offering is being underwritten solely by Goldman Sachs & Co. LLC and is expected to close on November 21, 2024, pending customary conditions. QuidelOrtho will not receive any proceeds from this offering, as all funds will go to the selling stockholder. The offering is made under an effective shelf registration statement filed with the SEC.
Read more →QDELAbout QuidelOrtho Corporation QuidelOrtho Corporation (Nasdaq QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more
QuidelOrtho Corporation has announced the appointment of Brian J. Blaser as its new President and Chief Executive Officer, effective May 6, 2024. Blaser brings over 25 years of leadership experience in the in-vitro diagnostics sector, previously serving as Executive Vice President at Abbott Laboratories. He expressed eagerness to lead the company through its next growth phase, emphasizing a commitment to customer service and improving healthcare outcomes. The Board of Directors also acknowledged the prior leadership during this transition period and is set to expand with Blaser's joining.
Read more →QDELQuidelOrtho Reports Second Quarter 2023 Financial Results Highligh ts Second quarter revenue of $665.1 million increased by 8% as reported with non-respiratory revenue up 3% on a supplemental combined basis (up 4% in con
QuidelOrtho Corporation reported its second quarter 2023 financial results, with total revenue of $665.1 million, reflecting an 8% increase compared to the previous year. However, while non-respiratory revenue grew by 9%, respiratory revenue saw a significant decline of 74%, leading to an adjusted EPS decrease of 88%. The company has completed important regulatory submissions and is focusing on further synergies from operational integration. Overall, the results indicate both a strong performance in certain areas and significant challenges in respiratory segments.
Read more →QDELQuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in cons
QuidelOrtho Corporation reported its financial results for Q1 2023, revealing a total revenue of $846.1 million, a significant decrease of 16% from the prior year. While non-respiratory revenue increased by 5%, respiratory sales plummeted by 72%. The company also reported a GAAP diluted EPS of $0.73, down dramatically from $11.31 in Q1 2022. Despite these challenges, QuidelOrtho's management expresses confidence in future growth, citing solid demand in its Labs business and effective integration efforts.
Read more →QDELQuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results Highlights Fourth quarter revenue of $866.5 million increased by 36% as reported and 19% on a supplemental combined basis, excluding COVID-19 revenu
QuidelOrtho Corporation reported its financial results for the fourth quarter and full year of 2022, highlighting substantial revenue growth. For Q4, revenue was $866.5 million, reflecting a 36% year-over-year increase, driven largely by performance in Point of Care and Molecular Diagnostics businesses. However, the company faced challenges, including a significant decrease in GAAP EPS compared to the previous year and adverse impacts from supply chain issues and COVID-19 related factors in the Labs segment. Overall, while the company reported robust revenue figures, profitability metrics showed concerning declines.
Read more →QDEL▲ +5.6%on this news
QUIDELORTHO ANNOUNCES SEPARATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER ROLES Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer an
QUIDELORTHO ANNOUNCES SEPARATION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER ROLES Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director Assumes role as President SAN DIEGO, CA - Quid
Read more →QDELQuidelOrtho Reports Third Quarter 2022 Financial Results Highlights Revenue of $783.8 million increased by 54% as reported Supplement al combined revenue of $783.8 million decreased by 21.8% in constant currency and incr
QuidelOrtho Reports Third Quarter 2022 Financial Results Revenue of $783.8 million increased by 54% as reported Supplemental combined revenue of $783.8 million decreased by 21.8% in constant currency and increased 3.0%, excluding COVID-19 revenue the transition of Beckman BNP a
Read more →QDELRanked among the world's largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint
QUIDELORTHO REPORTS PRELIMINARY REVENUE RESULTS FOR THIRD QUARTER 2022 QuidelOrtho to Report Third Quarter 2022 Financial Results on November 2, 2022 SAN DIEGO, CA - October 12, 2022 - QuidelOrtho Corporation (NASDAQ QDEL) (the "Company" or "QuidelOrtho"), a global provider of
Read more →QDEL▼ -5.1%on this news
among others, could cause actual results to differ from those set forth in the forward-looking statements the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the busi
QUIDELORTHO ANNOUNCES $300 MILLION SHARE REPURCHASE AUTHORIZATION Reflects QuidelOrtho's confidence in its strong balance sheet and cash generation QuidelOrtho continues to prioritize investments in R D, manufacturing capacity, and debt paydown SAN DIEGO, CA - August 17, 2022
Read more →QDELQuidelOrtho Reports Second Quarter 2022 Financial Results Highlights Revenue of $613.4 million increased by 247% as reported Supplement al combined revenue of $898.5 million increased by 37.5% in constant currency and 9.
QuidelOrtho Reports Second Quarter 2022 Financial Results Revenue of $613.4 million increased by 247% as reported Supplemental combined revenue of $898.5 million increased by 37.5% in constant currency and 9.0%, excluding COVID-19 revenue Strong growth in all business units, ex
Read more →Competitive Position
How QDEL ranks across every disease it competes inCompetitive Position is a premium feature
See how QDEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial